NomosLogic Inc

09/20/2026

Determinism in a computational system means one thing: the same input will produce the exact same output, every time. It is a simple concept with profound implications for drug discovery. This is not an argument against probabilistic models. Their ability to explore vast possibility spaces is essential for hypothesis generation. But the moment a decision is made to advance a candidate, to spend the next million dollars, to move toward the clinic, the logic must be deterministic. The creative, probabilistic engine can propose ten thousand doors. The analytical, deterministic engine is what tells you which nine thousand, nine hundred and ninety nine are locked. We need both, but we must be clear about which tool is right for which job.

09/12/2026

An inherited loss-of-function variant in a DNA mismatch repair gene presents a clear lesson in somatic evolution. The germline variant is not, by itself, oncogenic. Instead, it disables the primary cellular machinery for correcting replication errors. It removes the brakes on the somatic mutation rate.

This creates a state of genomic instability. The cell's normal operations begin to generate a steady stream of new mutations. Most of these are harmless passengers, but eventually, by pure chance, a mutation will arise in a proto-oncogene or a tumor suppressor. The germline variant provides the fertile ground for the subsequent somatic driver events.

This two-step mechanism, an inherited predisposition followed by a stochastic somatic event, explains the penetrance patterns we observe. The cancer risk is probabilistic, not deterministic, because the second hit is a random event. It also explains why the resulting tumors are often hypermutated, carrying thousands of somatic variants not present in the individual's healthy tissue.

09/09/2026

We are shifting the paradigm from fixing failure to optimizing outcomes before failure happens. Our infrastructure establishes the predictive foundation required to engineer therapeutic success at the molecular level.

https://youtu.be/1aorp1_2SBY?si=YogImJV1gtD3ZEGN

We are shifting the paradigm from fixing failure to optimizing outc...

09/09/2026

We have become exceptionally good at identifying statistical associations in human genetics. Genome-wide association studies can now pinpoint hundreds of loci linked to a complex trait. Our ability to interpret these findings mechanistically, however, lags far behind.
What is the biological meaning of a polygenic risk score? When risk is distributed across a thousand common variants, each with a tiny effect size, the classical model of a single broken component in a pathway no longer applies. It suggests a system that is subtly but broadly biased toward a disease state.
How do these small effects combine? Is the architecture simply additive, or are we missing key epistatic interactions? Does the risk manifest as a uniform five percent reduction in the efficiency of a pathway, or does it create a vulnerability that only becomes apparent under specific environmental stress? Answering this requires moving from statistical descriptions to predictive, dynamic models of the underlying networks.
ScientificMethod

09/09/2026

We have become exceptionally good at identifying statistical associations in human genetics. Genome-wide association studies can now pinpoint hundreds of loci linked to a complex trait. Our ability to interpret these findings mechanistically, however, lags far behind.
What is the biological meaning of a polygenic risk score? When risk is distributed across a thousand common variants, each with a tiny effect size, the classical model of a single broken component in a pathway no longer applies. It suggests a system that is subtly but broadly biased toward a disease state.
How do these small effects combine? Is the architecture simply additive, or are we missing key epistatic interactions? Does the risk manifest as a uniform five percent reduction in the efficiency of a pathway, or does it create a vulnerability that only becomes apparent under specific environmental stress? Answering this requires moving from statistical descriptions to predictive, dynamic models of the underlying networks.

09/07/2026

I was trained to believe that a sufficiently high-resolution genome would provide the ultimate explanation for disease. For a long time, my work reflected this belief, focusing almost exclusively on DNA as the source code for biology. I no longer think this is sufficient.

A genome describes a set of possibilities, not a guaranteed outcome. It is a blueprint for a complex machine, but it cannot tell you which parts are currently running, under what load, or how they are interacting with their environment. Without observing the downstream effects in the transcriptome, the proteome, and the resulting phenotype, the genome is a map of roads not taken.

My own work has shifted to demand this consilience. A genomic finding is now the beginning of an inquiry, not the end. A hypothesis is only considered strong when the genomic evidence is corroborated by orthogonal data from other biological modalities.

09/07/2026

Your DNA report shouldn't be a probability. It should be a proof.

Most genomic tools run your variants through a model and return a likelihood. NomosLogic doesn't. Our deterministic engine
— 496,805 proprietary variant mappings, 1.7M clinical logic objects, 362+ FDA drug-gene mandates, computes your pharmacogenomic profile.

Same input. Same output. Every time. Cryptographic audit trail on every result. This is what clinical-grade
actually means.

Vist https://Lite.nomoslogic.com to learn more. Prices starting from $99.

One-time payment. No subscription. Update your report any time you receive new labs, medication or diagnosis.


https://youtu.be/s47ErV8PbMI?si=uRG37UG-3IJoi_Pe

Dendrite Litehttps://lite.nomoslogic.comYou Already Have the Most...

09/06/2026

What a Method Is Willing to Reject
The real question in AI-driven drug discovery is not how much it can generate. It is how much
it is willing to throw away.
The industry has settled on a comfortable question: can a model design a better molecule? It is
comfortable because the answer is trending toward yes, and because a better molecule feels like the
whole game. It is the wrong question, or at least a shallow one. A generative system that proposes ten
thousand candidates has not done anything difficult. Proposing is cheap now. The difficult part, the
part that actually determines whether a discovery program is worth anything, is the discipline to kill
the candidates that do not survive contact with a real test, and to know exactly why each one died.
Trustworthiness in science is not set by what a method produces. It is set by what it is willing to reject.

09/06/2026

The real question in AI-driven drug discovery is not how much it can generate. It is how much
it is willing to throw away.
The industry has settled on a comfortable question: can a model design a better molecule? It is
comfortable because the answer is trending toward yes, and because a better molecule feels like the
whole game. It is the wrong question, or at least a shallow one. A generative system that proposes ten
thousand candidates has not done anything difficult. Proposing is cheap now. The difficult part, the part that actually determines whether a discovery program is worth anything, is the discipline to kill the candidates that do not survive contact with a real test, and to know exactly why each one died.

Trustworthiness in science is not set by what a method produces. It is set by what it is willing to reject. A hypothesis that cannot die is not a hypothesis. Consider a claim from the ferroptosis literature: that the curvature of a cell membrane could physically amplify the chain reaction of lipid peroxidation, so that the geometry of the membrane, not just its
chemistry, sets the speed of cell death. It is an interesting idea. What makes it a scientific idea, rather than a story, is that it can specify the exact measurement that would end it. Peroxidation rate in small, high-curvature vesicles versus large, low-curvature ones, at identical composition and identical radical flux. A threshold below which the effect is declared absent. A direction that, if reversed, disproves the mechanism outright regardless of the size of the effect.

The value of a hypothesis lives in that specification. A claim engineered to absorb any result is worthless no matter how sophisticated it sounds, because there is no world in which it is wrong, which means there is no world in which being right tells you anything.

The honest version of a hypothesis names three informative outcomes and no null result: every way the experiment can land teaches you something and sends you somewhere. The seductive version quietly reserves the right to reinterpret failure as partial success. In a manual research program a good scientist catches this by instinct. In an automated one that generates hypotheses faster than any human can read them, the instinct

The real question in AI-driven drug discovery is not how much it ca...

09/06/2026

When we target a protein with a small molecule, we are applying a strong selective pressure. We should therefore anticipate and model the evolutionary response. Instead of waiting for drug resistance to emerge clinically, we can computationally simulate the fitness landscape of the target protein before a program even enters optimization.

By exhaustively modeling the structural and energetic consequences of every possible single amino acid substitution in and around the binding site, it is possible to identify the mutations most likely to abrogate binding while preserving the protein's native function. This is not a trivial computational task, but it is a tractable one.

This in silico evolutionary simulation can generate a ranked list of likely escape mutations. This list can then be used to guide medicinal chemistry efforts, prioritizing compounds that maintain potency against the most probable resistance variants, or to design backup compounds pre-emptively.